Drug intelligence / Profile preview

ION826

Development stage: Unknown
Lead developer: Ionis Pharmaceuticals
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

ION826 is a Phase 2-ready antisense oligonucleotide developed by Ionis Pharmaceuticals. It targets lipoprotein(a) [Lp(a)] and is being developed for the treatment of cardiovascular disease. The drug leverages Ionis' proprietary LICA (Ligand Conjugated Antisense) technology. AstraZeneca licensed ION826 from Ionis in October 2023, in a deal that included an upfront payment and potential milestones totaling up to $1.5 billion, plus royalties.

Beyond the preview

Go deeper on ION826.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ION826.

Explore the full profile